The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Open accessAbstract
Purpose: Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapted therapy for stage III to IV classic Hodgkin lymphoma. Patients and Methods: The Southwest Oncology Group S0816 (Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma) trial enrolled 358 HIV-negative patients between July 1, 2009, and December 2, 2012. A PET scan was performed after two initial cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and was labeled PET2. PET2-negative patients (Deauville score 1 to 3) received an additional four cycles of ABVD, whereas PET2-positive patients (Deauville score 4 to 5) were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for six cycles. Among 336 eligible and evaluable patients, the median age was 32 years (range, 18 to 60 years), with 52% stage III, 48% stage IV, 49% International Prognostic Score 0 to 2, and 51% score 3 to 7. Results: Three hundred thirty-six of the enrolled patients were evaluable. Central review of the interim PET2 scan was performed in 331 evaluable patients, with 271 (82%) PET2-negative and 60 (18%) PET2-positive. Of 60 eligible PET2-positive patients, 49 switched to eBEACOPP as planned and 11 declined. With a median follow-up of 39.7 months, the Kaplan-Meier estimate for 2-year overall survival was 98% (95% CI, 95% to 99%), and the 2-year estimate for progression-free survival (PFS) was 79% (95% CI, 74% to 83%). The 2-year estimate for PFS in the subset of patients who were PET2-positive after two cycles of ABVD was 64% (95% CI, 50% to 75%). Both nonhematologic and hematologic toxicities were greater in the eBEACOPP arm than in the continued ABVD arm. Conclusion: Response-adapted therapy based on interim PET imaging after two cycles of ABVD seems promising with a 2-year PFS of 64% for PET2-positive patients, which is much higher than the expected 2-year PFS of 15% to 30%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Self-citationRevised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationAppio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
A Prognostic Score for Advanced Hodgkin's Disease
Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Björkholm, M., Brusamolino, E., Canellos, G. P., Carde, P., Crowther, D., Cunningham, D., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392104 · Cited by 1,736
Self-citationBarrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Self-citationTumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262
Self-citationGallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.-K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022473 · Cited by 838
Cited by
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d’Amore, F., Enblad, G., Franceschetto, A., Fulham, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510093 · Cited by 818
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichenauer, D. A., Aleman, B. M. P., André, M., Federico, M., Hutchings, M., Illidge, T., Engert, A., & Ladetto, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy080 · Cited by 431
Borchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Eichenauer, D. A., Zijlstra, J. M., Markova, J., Meissner, J., Feuring-Buske, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32134-7 · Cited by 393
Spina, V., Bruscaggin, A., Cuccaro, A., Martini, M., Di Trani, M., Forestieri, G., Manzoni, M., Condoluci, A., Arribas, A., Terzi-Di-Bergamo, L., et al. (2018) · Blood · doi:10.1182/blood-2017-11-812073 · Cited by 332
Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Ansell, S. M., Moskowitz, C. H., Fenton, K., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811224 · Cited by 322
Self-citation
Metadata
- Authors
- Press, O. W., Li, H., Schöder, H., Straus, D. J., Moskowitz, C. H., LeBlanc, M., Rimsza, L. M., Bartlett, N. L., Evens, A. M., Mittra, E. S., LaCasce, A. S., Sweetenham, J. W., Barr, P. M., Fanale, M. A., Knopp, M. V., Noy, A., Hsi, E. D., Cook, J. R., Lechowicz, M. J., Gascoyne, R. D., Leonard, J. P., Kahl, B. S., Cheson, B. D., Fisher, R. I., & Friedberg, J. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-06-10
- Volume
- 34
- Issue
- 17
- Pages
- 2020-2027
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2340968189
- Cited by
- 267
- References
- 24
- FWCI
- 35.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816. https://app.cochat.ai/papers/10.1200/jco.2015.63.1119
- The paper
- Press, O. W., Li, H., Schöder, H., Straus, D. J., Moskowitz, C. H., LeBlanc, M., Rimsza, L. M., Bartlett, N. L., Evens, A. M., Mittra, E. S., LaCasce, A. S., Sweetenham, J. W., Barr, P. M., Fanale, M. A., Knopp, M. V., Noy, A., Hsi, E. D., Cook, J. R., Lechowicz, M. J., . . . Friedberg, J. W. (2016). US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.63.1119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.